PUBLICATIONS
Britt NS, Hazlett DS, Horvat RT, Liesman RM, Steed ME. Activity of pulmonary vancomycin exposures versus planktonic and biofilm methicillin-resistant Staphylococcus aureus isolated from cystic fibrosis sputum. International Journal of Antimicrobial Agents. 2020 Jan [Epub ahead of print].
Impact Factor: 4.615
Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong, PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP. Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteremia. International Journal of Antimicrobial Agents. 2019 Sep;54(3):346-350.
Impact Factor: 4.615
Ahmed A, Schriever C, Britt N, Yager J, Amin R, McGuey L, Patel N. Comparing drug interaction frequencies of various hepatitis C treatment regimens among monoinfected patients. Annals of Hepatology. 2019 Jul/Aug;18(4):601-606.
Impact Factor: 1.895
Avery LM, Kuti JL, Weisser M, Egli A, Rybak MJ, Zasowski EJ, Arias CA, Contreras GA, Chong, PP, Aitken SL, DiPippo AJ, Wang JT, Britt NS, Nicolau DP. Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint. Clinical Infectious Diseases. 2019 May;68(10):1650-1657.
Impact Factor: 9.117
Seventh Place, Significant Publications in Infectious Diseases Pharmacotherapy (JPP), 2018
Roberts KL, Shuster JE, Britt NS, Balsara KR, Graetz TJ, Helwani M, Itoh A, Tellor BR. Evaluation of clinical outcomes after phosphodiesterase-5 inhibitor therapy for right ventricular dysfunction after left ventricular assist device implantation. American Society of Artificial Internal Organs Journal. 2019 Mar/Apr;65(3):264-269.
Impact Factor: 2.190
Britt NS, Ritchie DJ, Kollef MH, Burnham CD, Durkin MJ, Hampton NB, Micek ST. Clinical epidemiology of carbapenem-resistant gram-negative sepsis among hospitalized patients: shifting burden of disease? American Journal of Infection Control. 2018 Oct;46(10):1092-1096.
Impact Factor: 2.209
Britt NS, Ritchie DJ, Kollef MH, Burnham CD, Durkin MJ, Hampton NB, Micek ST. Importance of site of infection and antibiotic selection in the treatment of carbapenem-resistant Pseudomonas aeruginosa sepsis. Antimicrobial Agents and Chemotherapy. 2018 Mar 27;62(4).
Impact Factor: 4.415
Britt NS, Tirmizi S (co-first author), Ritchie DJ, Topal JE, McManus D, Nizet V, Casabar E, Sakoulas G. Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients. Journal of Antimicrobial Chemotherapy. 2018 Mar 1;73(3):764-767.
Impact Factor: 5.017
Britt NS, Hagopian JC, Brennan DC, Pottebaum AA, Santos CAQ, Gharabagi A, Horwedel TA. Effects of recurrent urinary tract infections on graft and patient outcomes after kidney transplantation. Nephrology Dialysis Transplantation. 2017 Oct 1;32(10):1758-1766.
Impact Factor: 4.470
Britt NS, Potter EM, McKinnell JA, Patel N, Battersby SE, Steed ME. Secular trends in nosocomial vancomycin-resistant enterococcal bloodstream infections among United States Veterans Affairs hospitals, fiscal years 2004 through 2014. Infection Control and Hospital Epidemiology. 2017 Sep 1;38(9):1114-1116.
Impact Factor: 3.550
Malek W, Yager J, Britt NS, Morse C, Hecox Z, Hoye-Simek A, Sullivan S, Patel N. Clinical outcomes associated with single tablet regimens: relationship between antiretroviral therapy pill burden and control of concomitant comorbidities among HIV-infected patients. 2017 [Epub].
Britt NS, Potter EM, Patel N, Steed ME. Effect of continuous and sequential therapy among Veterans receiving daptomycin or linezolid for vancomycin-resistant Enterococcus faecium bacteremia. Antimicrobial Agents and Chemotherapy. 2017 Apr 24;61(5).
Impact Factor: 4.415
Featured, Pharmacy Practice News
Britt NS, Potter EM, Patel N, Steed ME. Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients. Clinical Infectious Diseases. 2017 Mar 1;64(5):605-613.
Impact Factor: 8.216
Featured, New England Journal of Medicine (NEJM) Journal Watch
Seventh Place, Significant Publications in Infectious Diseases Pharmacotherapy (JPP), 2017
Nominee, Society of Infectious Diseases Pharmacists (SIDP) Pharmacotherapy Impact Paper of the Year, 2016
Britt NS, Patel N, Shireman TI, El Atrouni WI, Horvat RT, Steed ME. Relationship between vancomycin tolerance and clinical outcomes in Staphylococcus aureus bacteraemia. Journal of Antimicrobial Chemotherapy. 2017 Feb 1;72(2):535-542.
Impact Factor: 5.017
Britt NS, Potter EM. Clinical epidemiology of vancomycin-resistant Enterococcus gallinarum and Enterococcus casseliflavus bloodstream infections. Journal of Global Antimicrobial Resistance. 2016 Jun 1;5(1):57-61.
Impact Factor: 1.276
Britt NS, Patel N, Horvat RT, Steed ME. Vancomycin 24-hour area under the curve/minimum bactericidal concentration ratio as a novel predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia. Antimicrobial Agents and Chemotherapy. 2016 Apr 22;50(5).
Impact Factor: 4.415
Britt NS, Potter EM, Patel N, Steed ME. Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection; a national cohort study of Veterans Affairs patients. Clinical Infectious Diseases. 2015 Sep 15;61(6):871-888.
Impact Factor: 8.216
Featured, Editorial Commentary by McKinnell, et al.
Winner, American Society of Health-System Pharmacists (ASHP) Student Research Award, 2016
Winner, Society of Infectious Diseases Pharmacists (SIDP) Pharmacotherapy Impact Paper of the Year, 2015
First Place, Significant Publications in Infectious Diseases Pharmacotherapy (AJHP), 2015
Recommended, Faculty of 1000 Infectious Diseases
Britt NS, Steed ME, Potter EM, Clough LA. Tigecycline for the treatment of severe and severe complicated Clostridium difficile infection. Infectious Diseases and Therapy. 2014 Dec 1;3(2):321-331.
Impact Factor: 0.630
